scholarly journals Clinical characteristics of oral mucosal lesions in patients with systemic lupus erythematosus and their association with clinical and laboratory parameters

2021 ◽  
Vol 6 (2) ◽  
pp. 001-012
Author(s):  
Lilly Esquivel-Pedraza ◽  
Laura Fernández-Cuevas ◽  
Alba Cicero-Casarrubias ◽  
Sergio Ponce de León-Rosales ◽  
Mónica Fernández-Sánchez ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Laboratory Data ◽  
Oral Manifestations ◽  
Systemic Lupus ◽  
Cross Sectional ◽  
Laboratory Parameters ◽  
Oral Mucosal Lesions ◽  
Dna Antibodies ◽  
Mucosal Lesions

Introduction. Systemic lupus erythematosus (SLE) is an autoimmune disease that includes a broad spectrum of mucocutaneous manifestations. Objectives. To characterize the clinical spectrum of oral mucosal lesions in patients with SLE and to analize their association with clinical and laboratory parameters. Methods. We performed a cross-sectional study with systematic oral evaluations in SLE adult patients. Systemic and cutaneous lupus activities were recorded. We collected epidemiologic, clinical, and laboratory data. Statistical analysis included the kappa coefficient, X2 test, Fisher’s exact test and Mann-Whitney U-test, adjusting for multiple comparisons according to Bonferroni’s method. Results. A total of 181 patients (92.8% females) were included, with a median age of 37 (range 16-76) years. Cutaneous, systemic, and oral manifestations of lupus erythematosus (LE) activity were found in 31.5%, 23.8% and 18.8% of patients, respectively. Higher titres of anti-double-stranded (ds) DNA antibodies were detected in patients with LE-related oral lesions (LEOL) when compared to those without LEOL [356 (82-1083) UI vs 45 (0-417) UI; p=0.02). LEOL did not correlate to cutaneous (k=0.380) nor systemic (k=0.228) LE-activity (p<0.01). Conclusions. Oral manifestations related to SLE were significantly associated to anti double-ds DNA antibodies. LEOL were independent of cutaneous and systemic activity.

The prevalence of oral mucosal lesions and related factors in 188 patients with systemic lupus erythematosus

Lupus ◽  
2012 ◽  
Vol 21 (12) ◽  
pp. 1312-1315 ◽  
Author(s):  
M Khatibi ◽  
AH Shakoorpour ◽  
Z Moosavian Jahromi ◽  
A Ahmadzadeh
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Related Factors ◽  
Oral Mucosal Lesions ◽  
Mucosal Lesions

Systemic Lupus Erythematosus Presenting with Oral Mucosal Lesions – A Case Report

2009 ◽  
Vol 33 (3) ◽  
pp. 255-258 ◽  
Author(s):  
Y Ramakrishna ◽  
J Sharada Reddy
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Wide Spectrum ◽  
Female Child ◽  
Membrane Phospholipids ◽  
Systemic Lupus ◽  
Autoimmune Rheumatic Disease ◽  
Child Bearing ◽  
Oral Mucosal Lesions ◽  
Mucosal Lesions

Systemic Lupus Erythematosus (SLE) is an autoimmune rheumatic disease, principally affecting women during child bearing years and is characterized by the presence of auto antibodies against a variety of auto antigens such as double-stranded DNA, intracellular ribonuclear proteins and membrane phospholipids. The presentation of lupus erythematosus ranges from a skin rash unaccompanied by extracutaneous stigmata to a rapidly progressive lethal multiorgan disease. A wide spectrum of oral mucosal lesions is found in the cutaneous and systemic forms of lupus erythematosus. We report a 11-year-old female child with classical features of Systemic Lupus Erythematosus associated with oral mucosal lesions.

Systemic lupus erythematosus presenting with oral mucosal lesions: easily missed?

2001 ◽  
Vol 144 (6) ◽  
pp. 1219-1223 ◽  
Author(s):  
C.H. Orteu ◽  
J.A.G. Buchanan ◽  
I. Hutchison ◽  
I.M. Leigh ◽  
R.H. Bull
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Oral Mucosal Lesions ◽  
Mucosal Lesions

scholarly journals The prevalence of oral mucosal lesions and related factors in systemic lupus erythematosus patients

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Mayssoun Kudsi ◽  
Louei Darjazini Nahas ◽  
Rama Alsawah ◽  
Ahmad Hamsho ◽  
Abdullah Omar
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Clinical Examination ◽  
Lupus Erythematosus ◽  
Oral Lesions ◽  
Systemic Lupus ◽  
Related Factors ◽  
Wide Range ◽  
Significant Difference ◽  
Oral Mucosal Lesions ◽  
Mucosal Lesions

Abstract Background Systemic lupus erythematosus (SLE) is a chronic inflammatory multi systematic disease of unknown aetiology. SLE has a wide range of symptoms. The most common symptoms are joint pain, skin rash and fever. Oral lesions in SLE manifest in a variety of forms, such as oral mucosal ulceration, mouth burns, xerostomia and salivary gland diseases, temporomandibular joint disease, periodontal disease, dysgeusia, white lesions, oedema, bleeding and petechiae. Objective This study was conducted to evaluate the prevalence of oral mucosal lesions and their related factors in patients with SLE, giving the lack of comprehensive statistical data in Syria and the differences between reported prevalence. Patients and methods A cross-sectional study was performed in the Al-Mouassat University Hospital in Damascus. Patients were evaluated appropriating observation, clinical examination, completing questionnaires, studying patient’s medical records and paraclinical laboratory tests if required. Four types of oral lesions were evaluated: ulcer, erythema, white plaque and spots. The diagnosis of these lesions was made according to observation and clinical examination, and the location of each lesion was also recorded. Data were analysed using SPSS version 16.0. Result In this study, 42 (70% %) out of 60 patients (38 women and 4 men) had oral lesions, while 18 (30%) had none. The most common areas for the lesions were the buccal mucosa (26.1%) and the lips (14.2%). Of the 42 patients with oral lesions, 12 (27.6%) showed ulcers. There was a significant relationship between the following factors and oral lesions: oral hygiene status, the duration of the disease involvement, frequency of pregnancies, the amount of daily use of corticosteroids without significant difference between dosage groups, and medications used for SLE treatment other than corticosteroids (p < 0.008) without mentioned names or dosages. Conversely, age, sex, cigarette smoking and medications other than those used for SLE treatment were not significantly related to the presence of oral lesions (p value was greater than 0.05 in all subjects).

scholarly journals THU0257 ESTIMATED 10-YEARS CARDIOVASCULAR RISK IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: PRELIMINARY RESULTS FROM THE “CARDIOVASCULAR OBESITY AND RHEUMATIC DISEASE (CORDIS)” STUDY GROUP OF THE ITALIAN SOCIETY OF RHEUMATOLOGY.

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 355.2-356
Author(s):  
F. Cacciapaglia ◽  
A. Manfredi ◽  
G. Erre ◽  
E. Bartoloni Bocci ◽  
G. Sakellariou ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
High Risk ◽  
Lupus Erythematosus ◽  
Laboratory Data ◽  
Cross Sectional Study ◽  
Systemic Lupus ◽  
Cross Sectional ◽  
Female Age ◽  
The Mean ◽  
First Time

Background:Systemic lupus erythematosus (SLE) patients are at high risk for CV events, and EULAR recommends assessing the 10-year CV-risk using the Systematic Coronary Risk Evaluation (SCORE) [1]. The QRISK3, another score to assess CV-risk in UK population, considers different factors among which also SLE. The Progetto Cuore score (PCS) is validated to estimate CV risk in Italian people and largely replicates the SCORE project [2].Objectives:This cross-sectional study aimed to estimate CV-risk using SCORE, QRISK3 and, for the first time, PCS in a multicentric cohort of Italian SLE patients.Methods:During 2019 we evaluated 173 SLE patients (87.7% female; age 40±16 years; disease duration 138±105 months), fulfilling the 1997 ACR classification criteria. Clinical and laboratory data were registered, and individual CV-risk was calculated using suitable algorithms for the SCORE, QRISK3 and PCS. Statistical analysis was performed using Graphpad Instat 8.0 (San Diego, CA-USA).Results:In 13 (7%) SLE patients a previous CV event was recorded. Hypertension was present in 60 (37.5%) and diabetes in 27 (16.9%) patients. Mean total cholesterol was 184±39 mg/dL, HDLc 58±18 mg/dL, LDLc 124±37 mg/dL, triglycerides 105±63 mg/dL; dyslipidaemia was reported in 58 (36.2%) patients and 29 (18.1%) were on statin. Mean BMI was 24.9±5.3 Kg/sm, 60 (37.5%) and 23 (14.3%) patients were overweight and obese, while 25 (15.6%) patients were smokers. 87 (54.3%) SLE patients had a SLEDAI<4, 91% of patients were taken HCQ and 65% were on prednisone (mean dose 5.4±5.9 mg/day), but only 7.5% took >7.5 mg/day. The CV-risk of SLE patients according to SCORE, QRISK3 and PCS was 1.1±2.1%, 10.5±12.3% and 3.7±5.4%, respectively. Stratifying patients at low, moderate or high CV risk according to the PCS and SCORE a double proportion of patients was at moderate (8% vs 3.9%) or high (1.9% vs 0.9%) CV risk (p=0.03). Finally, CV-risk according to QRISK3 was higher than 20% (high risk) in 32/160 (20%) patients.Conclusion:This multicentre study demonstrated that the mean estimated CV-risk in SLE patients is globally low using the SCORE, QRISK3 and PCS. The PCS seems to better intercept those patients at moderate/high risk, at least in Italian SLE patients, while QRISK3 predicts the highest CV risk. The lack of disease-specific CV-risk factors (such as autoantibodies profile or organ involvement) probably account for the underestimation of CV risk using the SCORE and PCS.References:[1]ARD 2019;78(6):736-745.[2]ARD 2019;0:1–2.doi:10.1136/annrheumdis-2019-215715Disclosure of Interests:Fabio Cacciapaglia Speakers bureau: BMS; Roche; Pfizer; Abbvie, Andreina Manfredi: None declared, Gianluca Erre: None declared, Elena Bartoloni Bocci: None declared, Garifallia Sakellariou Speakers bureau: Abbvie, Novartis, MSD, Ombretta Viapiana: None declared, Sergio Colella: None declared, Anna Abbruzzese: None declared, Marco Fornaro: None declared, Giacomo Cafaro: None declared, Maria Antonietta Fenu: None declared, Bianca Lucia Palermo: None declared, Martina Dessì: None declared, Adalgisa Palermo: None declared, Alessandro Giollo: None declared, Elisa Gremese Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Sanofi, UCB, Roche, Pfizer, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Sanofi, UCB, Roche, Pfizer, Francesca Romana Spinelli Grant/research support from: Pfizer, Speakers bureau: Lilly, BMS, Celgene, Fabiola Atzeni: None declared, Matteo Piga: None declared

scholarly journals Prevalence of Oral Manifestations in Systemic Lupus Erythematosus Patients Referred to Shahid Mohammadi Hospital in 2018 - 2019

2021 ◽  
Vol 13 (2) ◽  
Author(s):  
Raziyehsadat Rezvaninejad ◽  
Majid Dadmehr ◽  
Rayehehossadat Rezvaninejad
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Disease ◽  
Clinical Manifestations ◽  
Dorsal Surface ◽  
Oral Manifestations ◽  
Systemic Lupus ◽  
Cross Sectional ◽  
Local Skin ◽  
Bandar Abbas

Background: The oral mucosa is damaged in a significant percentage of patients with lupus, with the main oral lesions being ulcers, erythematous lesions, and discoid lesions. The prevalence of these lesions is estimated to vary from 9% to 45% in systemic disease and 3% to 20% in local skin disease. Objectives: One of the symptoms of lupus is its oral manifestations. Therefore, we decided to conduct a study to investigate the prevalence of oral manifestations in lupus patients referred to Shahid Mohammadi Hospital in Bandar Abbas. Methods: In this descriptive cross-sectional study, the recorded information of patients with lupus referred to Shahid Mohammadi Hospital in Bandar Abbas from 2018 to 2019 was reviewed. All enrolled patients met the American College of Rheumatology criteria for classifying lupus. Recorded information, including demographic characteristics and various clinical manifestations, was recorded after examining the patients. Data were analyzed using SPSS-22 software. Results: A total of 76 patients were studied. Of them, 23 (30.2%) were males, and 53 (69.8%) were females. The mean age of the participants was 6.1 ± 42.9. The most common site of oral lesion in the participants was the lip area (36 patients), followed by buccal mucosa (22 patients), hard palate (14 patients), and dorsal surface of the tongue (four patients). The majority of the clinical manifestations of the lesion were wounds (36 individuals), followed by white and red lesions (20 patients), non-cleansing white lesions (12 patients), and red lesions (eight individuals). Conclusions: Oral symptoms are usually the first signs of this disease. For this reason, dentists have an important role to play in diagnosing emerging autoimmune diseases. Ulcers are the most prevalent clinical manifestations, according to this study, and the lips are the most prevalent location. As a result, in patients with systemic lupus erythematosus, these two findings should be given greater importance than others.

scholarly journals Pulmonary Involvement in Children With Systemic Lupus Erythematosus

2021 ◽  
Vol 8 ◽  
Author(s):  
Ge Dai ◽  
Linlin Li ◽  
Ting Wang ◽  
Wujun Jiang ◽  
Jie Ma ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Laboratory Data ◽  
Ground Glass Opacity ◽  
Pulmonary Involvement ◽  
Systemic Lupus ◽  
Duration Of Symptoms ◽  
Laboratory Parameters ◽  
Few Data ◽  
Interlobular Septal Thickening

Background: Symptomatic pulmonary involvement in systemic lupus erythematosus (SLE) seems not uncommon in children. However, there are few data on the characteristics and laboratory parameters of SLE patients with pulmonary involvement.Methods: This was a hospital-based study involving 111 SLE patients from 1 January 2012 to 31 December 2016. The demographic, clinical, and laboratory data of the patients were prospectively collected. They were followed as outpatients until December 2019. Clinical characteristics and laboratory parameters of patients with and without pulmonary involvement were compared.Results: Of the 111 patients with SLE, we identified 18 patients (16.2%) with pulmonary involvement. The most common HRCT findings were ground glass opacity, interlobular septal thickening, bilateral diffuse infiltrates, and pleurisy/pleural effusion (55.6, 50, 50, and 44.4%, respectively). SLE patients with pulmonary involvement tended to have a longer disease duration (14 [12–24.5] vs. 5 [2–9] months, P &lt; 0.01). We also observed a significant association between the presence of anti-Sm antibody, ANCA, Anti-RNP and the presence of pulmonary involvement of SLE (all P &lt; 0.001).Conclusions: Lung involvement was frequent in SLE patients from Southeast China. Patients with a longer duration of symptoms before SLE diagnosis tended to have pulmonary involvement. When children with SLE are found to have anti-RNP antibody and positive ANCA, it should be alert to the occurrence of pulmonary involvement.

Clinical case of lung lesions in patient with newly diagnosed systemic lupus erythematosus

2019 ◽  
Vol 1 (9) ◽  
pp. 53-57
Author(s):  
T. N. Gavva ◽  
L. V. Kuzmenkova ◽  
Yu. N. Fedulaev ◽  
T. V. Pinchuk ◽  
D. D. Kaminer ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Clinical Case ◽  
Clinical Manifestations ◽  
Lung Damage ◽  
Newly Diagnosed ◽  
Systemic Lupus ◽  
Lung Lesions ◽  
Laboratory Parameters ◽  
Clinical Interest

A case of lung damage in systemic lupus erythematosus (SLE) in a 33-year-old woman is described. This case is of clinical interest due to the complexity of diagnosis due to the fact that SLE is a disease with diverse clinical manifestations involving many organs and systems, which often makes it difficult to timely recognize the onset of the disease. SLE still remains a challenge and requires special attention to the patient s history, clinical and laboratory parameters of the patient, as well as specific immunological examinations.

Sign in / Sign up

Export Citation Format

Share Document